Pemziviptadil (pb1046) (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 86 | Pulmonary arterial hypertension | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03795428 (ClinicalTrials.gov) | April 10, 2019 | 18/12/2018 | Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004 | A Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Study PB1046-PT-CL-0004 | Pulmonary Arterial Hypertension | Drug: Pemziviptadil (PB1046) Injection | PhaseBio Pharmaceuticals Inc. | NULL | Recruiting | 18 Years | 79 Years | All | 63 | Phase 2 | United States |
| 2 | NCT03556020 (ClinicalTrials.gov) | July 15, 2018 | 1/6/2018 | Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH | A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension | Drug: Pemziviptadil (PB1046) | PhaseBio Pharmaceuticals Inc. | NULL | Recruiting | 18 Years | 79 Years | All | 63 | Phase 2 | United States |